Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the US Market
27 December 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NYSE: RDY) has launched Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market following approval from the US Food and Drug Administration (USFDA), the company said.

The Aggrenox brand and generic had US sales of approximately USD 182m MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size.
Aggrenox is a trademark of Germany's Boehringer Ingelheim.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, offering a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include USA, India, Russia and CIS countries, and Europe.